Keywords: Eli Lilly, Kyowa, Livalo, Statin, Licensing, USA, Latin America

Lilly in deal with Kowa to co-promote newly-approved statin Livalo in USA and commercialization rights for Latin America

Article | 24 December 2009

• Print This

US drug major Eli Lilly has signed an accord with Kowa Pharmaceuticals America, the US subsidiary of Japan’s Kyowa, to commercialize Livalo (pitavastatin). The companies have also entered into a licensing agreement in Latin America. Financial terms of the deal have not been disclosed.

Livalo is a cholesterol-lowering statin which was approved by the US Food and Drug Administration in August this year for the treatment of primary hyperlipidemia and mixed dyslipidemia.

Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here.

Under the terms of the deal, Kowa Pharmaceuticals America will receive an undisclosed upfront payment. Lilly and Kowa Pharmaceuticals America will co-promote Livalo in the US market, with both companies providing sales force resources and sharing development and marketing costs. Kowa Pharmaceuticals America will record all US sales of the drug and will pay Lilly an escalating co-promotion fee based on the level of annual net sales. In addition, Lilly has acquired an exclusive license from Kowa to commercialize Livalo in Latin American markets, including Mexico, Central America and South America